CA
NZ
UK
AU
IND
US
…
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 193.40M | 274.38M | 263.74M | 234.17M | 213.78M |
| Minority interest | - | - | -0.02M | -0.02M | -0.02M |
| Net income | 143.50M | 229.65M | 240.30M | 196.22M | 193.54M |
| Selling general administrative | 657.40M | 395.29M | 369.06M | 314.66M | 289.46M |
| Gross profit | 1058.80M | 808.35M | 743.07M | 629.17M | 574.89M |
| Reconciled depreciation | 136.10M | 35.62M | 29.30M | 23.49M | 21.13M |
| Ebit | 210.00M | 275.82M | 255.82M | 221.22M | 208.89M |
| Ebitda | 346.10M | 311.44M | 284.18M | 244.70M | 230.02M |
| Depreciation and amortization | 136.10M | 35.62M | 28.35M | 23.49M | 21.13M |
| Non operating income net other | -16.60M | -1.44M | 7.91M | 12.95M | 5.73M |
| Operating income | 210.00M | 275.82M | 255.82M | 221.22M | 208.04M |
| Other operating expenses | 1825.80M | 963.33M | 888.39M | 716.62M | 649.82M |
| Interest expense | 25.70M | 0.35M | 0.34M | 0.33M | 4.88M |
| Tax provision | 49.90M | 44.73M | 23.45M | 37.95M | 20.23M |
| Interest income | 1.80M | 0.94M | 5.53M | 13.92M | - |
| Net interest income | -23.90M | 0.58M | 5.20M | 13.59M | - |
| Extraordinary items | - | - | - | - | -0.90M |
| Non recurring | - | - | -0.47M | - | 0.42M |
| Income tax expense | 49.90M | 44.73M | 23.45M | 37.95M | 20.23M |
| Total revenue | 2035.80M | 1239.15M | 1143.74M | 937.84M | 858.29M |
| Total operating expenses | 848.80M | 532.52M | 487.72M | 407.96M | 366.42M |
| Cost of revenue | 977.00M | 430.81M | 400.68M | 308.67M | 283.40M |
| Total other income expense net | -16.60M | -1.44M | 7.91M | 12.95M | 5.31M |
| Net income from continuing ops | 143.50M | 229.65M | 240.28M | 196.22M | 193.54M |
| Net income applicable to common shares | 143.50M | 229.65M | 240.30M | 196.22M | 193.54M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3041.50M | 3210.60M | 1887.01M | 1712.55M | 1396.13M |
| Intangible assets | 1204.60M | 722.60M | 72.50M | 73.92M | 27.25M |
| Other current assets | 99.90M | 158.80M | 91.03M | 102.42M | 60.07M |
| Total liab | 1676.70M | 1871.70M | 336.76M | 304.91M | 228.25M |
| Total stockholder equity | 1364.80M | 1338.90M | 1550.24M | 1407.66M | 1167.87M |
| Deferred long term liab | - | 17.10M | 28.09M | 20.08M | 5.26M |
| Other current liab | 222.40M | 238.80M | 134.86M | 118.86M | 87.08M |
| Common stock | 0.10M | 0.10M | 0.06M | 0.06M | 0.05M |
| Capital stock | 0.10M | 0.10M | 0.06M | 0.06M | 0.05M |
| Retained earnings | 1795.80M | 1714.30M | 1570.86M | 1341.23M | 1100.49M |
| Other liab | - | 246.70M | 69.03M | 71.08M | 40.20M |
| Good will | 407.70M | 445.40M | 100.33M | 103.21M | 22.35M |
| Other assets | - | 0.30M | 202.97M | 161.75M | 105.30M |
| Cash | 166.00M | 202.90M | 745.25M | 641.45M | 567.69M |
| Total current liabilities | 563.80M | 630.00M | 267.74M | 233.84M | 172.22M |
| Current deferred revenue | 37.40M | 80.60M | 50.88M | 44.94M | 25.94M |
| Net debt | 804.00M | 772.50M | -712.59M | -607.10M | -547.20M |
| Short term debt | 52.50M | 33.80M | 6.37M | 5.97M | 4.65M |
| Short long term debt | 34.30M | 15.10M | - | - | - |
| Short long term debt total | 970.00M | 975.40M | 32.66M | 34.35M | 20.49M |
| Other stockholder equity | -385.80M | -387.00M | -15.14M | 64.96M | 74.04M |
| Property plant equipment | - | 402.50M | 272.79M | 272.51M | 219.55M |
| Total current assets | 1231.90M | 1308.60M | 1238.41M | 1101.16M | 996.06M |
| Long term investments | 9.90M | 13.80M | 13.83M | 8.00M | 6.47M |
| Net tangible assets | - | 631.50M | 1377.41M | 1230.53M | 1118.27M |
| Short term investments | - | - | - | 0.00M | 120.00M |
| Net receivables | 421.00M | 445.90M | 200.76M | 141.35M | 132.43M |
| Long term debt | 871.70M | 941.60M | - | - | - |
| Inventory | 545.00M | 501.00M | 201.37M | 215.95M | 115.87M |
| Accounts payable | 251.50M | 276.80M | 75.63M | 64.06M | 54.55M |
| Noncontrolling interest in consolidated entity | - | - | - | -0.02M | - |
| Accumulated other comprehensive income | -45.30M | 11.50M | -5.53M | 1.41M | -6.72M |
| Common stock total equity | - | 0.10M | 0.06M | 0.06M | 0.05M |
| Retained earnings total equity | - | 1714.30M | 1570.86M | 1341.23M | 1100.49M |
| Treasury stock | - | -1169.20M | -767.65M | -638.74M | -526.58M |
| Non currrent assets other | -506.80M | 215.20M | 136.53M | 114.38M | 88.47M |
| Deferred long term asset charges | - | - | - | - | 35.97M |
| Non current assets total | 1809.60M | 1902.00M | 648.60M | 611.39M | 400.07M |
| Capital lease obligations | 64.00M | 72.10M | 32.66M | 34.35M | 20.49M |
| Long term debt total | - | 941.60M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1057.70M | -2.60M | 120.00M | -120.00M | -26.15M |
| Change to liabilities | 71.10M | 18.10M | 42.01M | 29.87M | 11.96M |
| Total cashflows from investing activities | -1057.70M | -37.53M | -82.79M | -197.68M | -26.15M |
| Net borrowings | 939.20M | 948.50M | 948.50M | 948.50M | - |
| Total cash from financing activities | 520.30M | -122.40M | -54.31M | -9.34M | 25.78M |
| Change to operating activities | -59.80M | -8.55M | -17.06M | -9.29M | -7.14M |
| Net income | 143.50M | 229.65M | 240.28M | 196.22M | 193.54M |
| Change in cash | -538.80M | 103.37M | 76.93M | 15.43M | 237.16M |
| Begin period cash flow | 748.40M | 645.00M | 568.08M | 552.64M | 315.48M |
| End period cash flow | 209.60M | 748.38M | 645.00M | 568.08M | 552.64M |
| Total cash from operating activities | 29.50M | 264.75M | 210.96M | 221.64M | 239.53M |
| Issuance of capital stock | 8.10M | 23.24M | 58.42M | 28.34M | 44.75M |
| Depreciation | 136.10M | 35.62M | 29.30M | 23.49M | 21.13M |
| Other cashflows from investing activities | -1004.90M | -2.60M | -130.24M | -9.31M | -9.03M |
| Change to inventory | -155.90M | 13.49M | -94.43M | -21.26M | -1.89M |
| Change to account receivables | -138.50M | -60.80M | -2.23M | -23.58M | 10.83M |
| Sale purchase of stock | -401.50M | -128.92M | -110.54M | -37.55M | -18.48M |
| Other cashflows from financing activities | 1049.10M | -16.73M | -2.19M | -0.12M | -0.49M |
| Change to netincome | 10.20M | 30.83M | 37.90M | 34.31M | 19.65M |
| Capital expenditures | 56.30M | 34.93M | 79.96M | 72.49M | 22.68M |
| Change receivables | -138.50M | -60.80M | -2.23M | -23.58M | 10.83M |
| Cash flows other operating | -38.50M | -17.17M | -41.86M | -17.41M | -15.70M |
| Cash and cash equivalents changes | -507.90M | 104.82M | 73.87M | 14.62M | 239.16M |
| Change in working capital | -261.80M | -31.34M | -96.52M | -32.38M | 7.22M |
| Stock based compensation | 47.70M | 44.62M | 42.23M | 39.23M | 27.42M |
| Other non cash items | 3.30M | 1.29M | 0.64M | 1.04M | -1.51M |
| Free cash flow | -26.80M | 229.82M | 131.01M | 149.15M | 216.84M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
-0.71 0.65% |
108.58 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
0.28 0.28% |
101.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-2.16 0.68% |
316.63 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.31 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph E. Kiani | Founder, CEO & Chairman | 1965 |
| Mr. Micah Young | Exec. VP of Fin. & CFO | 1979 |
| Mr. Bilal Muhsin | Chief Operating Officer | 1981 |
| Mr. Thomas Samuel McClenahan | Exec. VP, Gen. Counsel & Corp. Sec. | 1973 |
| Mr. Tao Leopold Levy | Exec. VP of Bus. Devel. | 1974 |
| Mr. Yongsam Lee | Exec. VP & Chief Information Officer | 1965 |
| Dr. Steven J. Barker | Chairman of Scientific Advisory Board & Chief Science Officer | 1945 |
| Mr. Eli Kammerman | VP of Bus. Devel. & Investor Relations | NA |
| Mr. Jon Coleman | Pres of Worldwide Sales, Professional Services & Medical Affairs | 1964 |
| Mr. Anand Sampath | Exec. VP of Operations & Clinical Research | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...